ABC News, 27/04/16, 5:12pm
A groundbreaking new drug tipped to stop the spread of HIV within just a few years will be available to more than 2,000 Queensland men under a $6 million trial program.
The trials make Pre-Exposure Prophylaxis (PrEP) available to men who have sex with men, as a means of preventing HIV transmission.
Read more here
Almost-certain case of PrEP failure due to drug resistance
nam/aidsmap, 25 February 2016
A case report of a man in Toronto who became infected with a multi-drug-resistant strain of HIV despite apparently very consistent adherence to PrEP was presented at the CROI 2016 conference in Boston today.
Read more here
London sexual health clinics step up their support for people buying PrEP online
nam/aidsmap, 29 January 2016 Several large sexual health clinics in London and Brighton have responded to the growing numbers of people importing PrEP medications from overseas by offering free safety monitoring to PrEP users. This is in a context of increasing frustration with the slowness of the official NHS process to approve PrEP – no decision will be made until June at the earliest. Read...
Ipergay PrEP study results published
NAM , 02 December 2015 The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional...
Large Study of PrEP Use in Clinical Practice Shows No New HIV Infections
PR Newswire, September 2, 2015 In one of the first and largest published evaluations of the use of preexposure prophylaxis (known as PrEP) to prevent HIV infection in a clinical practice setting, researchers at Kaiser Permanente found no new HIV infections among patients during more than 2.5 years of observation. The study was published today in the journal Clinical Infectious Diseases. Read more...
PrEP Is Safe for People With Hepatitis B
AIDSMEDS, August 17, 2015
People with hepatitis B virus (HBV) can safely take Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP), as it does not lead to liver inflammation “flares” or other health problems when it is used or discontinued.
Read more here